利妥昔单抗与HBsAg阴性/抗-HBc阳性肾移植受者乙型肝炎再激活
该研究分析2008至2014年间172例接受活体供肾移植的已消退HBV感染患者,分为利妥昔单抗组49例和对照组123例。中位随访58个月,利妥昔单抗组5例(10.2%)发生HBV再激活,对照组2例(1.6%),差异有统计学意义(P=0.003)。利妥昔单抗脱敏(HR 9.18)和乙肝表面抗体状态(HR 4.74)为HBV再激活的显著危险因素。
要点
- 利妥昔单抗脱敏组HBV再激活率10.2%(5/49),对照组1.6%(2/123),P=0.003。
- 利妥昔单抗组2例发生HBV相关重型肝炎,1例死于肝衰竭;对照组无重型肝炎。
- 利妥昔单抗脱敏(HR 9.18)和乙肝表面抗体状态(HR 4.74)为再激活显著危险因素。
核心结论
- 对HBsAg阴性/抗-HBc阳性患者,不相容肾移植的利妥昔单抗脱敏显著增加HBV再激活风险。
- 因此,这些患者需要密切监测HBV DNA。
研究设计与样本
- 回顾性分析2008至2014年间接受活体供肾移植的172例已消退HBV感染患者。
- 患者分为利妥昔单抗组(n=49)和对照组(n=123)。
- 观察HBV再激活,定义为乙肝表面抗原或HBV DNA再次出现。
主要发现
- 中位随访58个月(范围4-95个月),利妥昔单抗组5例(10.2%)发生HBV再激活,对照组2例(1.6%),P=0.003。
- 利妥昔单抗组2例发生HBV相关重型肝炎,1例死于肝衰竭;对照组无患者发生重型肝炎。
- 从利妥昔单抗脱敏至HBV再激活的中位时间为11个月(范围5-22个月)。
- 两组乙肝表面抗体状态相似。
- 利妥昔单抗脱敏(HR 9.18;95%CI 1.74-48.86;P=0.009)和乙肝表面抗体状态(HR 4.74;95%CI 1.05-21.23;P=0.04)为HBV再激活的显著危险因素。
临床怎么用
- 对HBsAg阴性/抗-HBc阳性接受利妥昔单抗脱敏的肾移植患者,需要密切监测HBV DNA。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy. Although rituximab is increasingly used for desensitization of ABO-incompatible or positive crossmatch kidney transplantation, the risk of HBV reactivation in hepatitis B surface antigen (HBsAg)-negative/hepatitis B core antibody (anti-HBc)-positive kidney transplant patients receiving rituximab desensitization remains undetermined. METHODS: We analysed 172 resolved HBV patients who underwent living donor kidney transplantation between 2008 and 2014. Patients were divided into rituximab ( n = 49) or control ( n = 123) groups. All patients were observed for HBV reactivation, which was defined as the reappearance of hepatitis B surface antigen or HBV DNA. RESULTS: During the follow-up period (median, 58 months; range, 4-95 months), five patients (10.2%) in the rituximab group and two patients (1.6%) in the control group experienced HBV reactivation (P = 0.003). In the rituximab group, two patients experienced HBV-related severe hepatitis, and one patient died due to hepatic failure. The median time from rituximab desensitization to HBV reactivation was 11 months (range, 5-22 months). By contrast, no patients in the control group experienced severe hepatitis. The status of hepatitis B surface antibody was similar between groups. Rituximab desensitization [hazard ratio (HR), 9.18; 95% confidence interval (CI), 1.74-48.86; P = 0.009] and hepatitis B surface antibody status (HR, 4.74; 95% CI, 1.05-21.23, P = 0.04) were significant risk factors for HBV reactivation. CONCLUSIONS: Rituximab desensitization for incompatible kidney transplantation significantly increased the risk of HBV reactivation in HBsAg-negative/anti-HBc-positive patients. Therefore, close monitoring of HBV DNA is required in these patients.
引用
- Lee J, Park JY, Huh KH, et al. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients. Nephrol Dial Transplant. 2017. PMID: 28339910. doi:10.1093/ndt/gfw455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。